Sean Gaskell - Alvotech Warrant Chief Officer
| ALVOW Stock | USD 2.55 0.26 9.25% |
Insider
Sean Gaskell is Chief Officer of Alvotech Warrant
| Age | 42 |
| Address | 9, Rue de Bitbourg, Luxembourg City, Luxembourg, 1273 |
| Phone | 354 422 4500 |
| Web | https://www.alvotech.com |
Alvotech Warrant Management Efficiency
The company has return on total asset (ROA) of (0.0761) % which means that it has lost $0.0761 on every $100 spent on assets. This is way below average. Alvotech Warrant's management efficiency ratios could be used to measure how well Alvotech Warrant manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.63 in 2024. Return On Capital Employed is likely to drop to -0.54 in 2024. At this time, Alvotech Warrant's Intangible Assets are fairly stable compared to the past year. Intangibles To Total Assets is likely to climb to 0.05 in 2024, whereas Non Current Assets Total are likely to drop slightly above 610.3 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Carla Poulson | Mersana Therapeutics | N/A | |
| Ronald Evans | Syndax Pharmaceuticals | 75 | |
| Alvin Pharmd | Puma Biotechnology | 71 | |
| Michael Downes | Syndax Pharmaceuticals | N/A | |
| Igor Bilinsky | Iovance Biotherapeutics | 51 | |
| Henric Bjarke | Inozyme Pharma | 57 | |
| Charles II | Day One Biopharmaceuticals | 47 | |
| JeanMarc MBA | Iovance Biotherapeutics | 52 | |
| MSc MBA | Inozyme Pharma | 52 | |
| Mike Preigh | Day One Biopharmaceuticals | N/A | |
| Melissa MBA | Zentalis Pharmaceuticals Llc | 45 | |
| Carrie MD | Zentalis Pharmaceuticals Llc | 54 | |
| Esq JD | Iovance Biotherapeutics | 48 | |
| MBA MBA | Inozyme Pharma | 65 | |
| Alexander Nolte | Syndax Pharmaceuticals | 51 | |
| Kimberly MD | Zentalis Pharmaceuticals Llc | 55 | |
| Julie MBA | Day One Biopharmaceuticals | 42 | |
| Meena Rao | Zentalis Pharmaceuticals Llc | N/A | |
| Briggs MD | Syndax Pharmaceuticals | 64 | |
| MA MS | Inozyme Pharma | N/A | |
| Friedrich MD | Iovance Biotherapeutics | 57 | |
Management Performance
| Return On Asset | -0.0761 |
Alvotech Warrant Leadership Team
Elected by the shareholders, the Alvotech Warrant's board of directors comprises two types of representatives: Alvotech Warrant inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alvotech. The board's role is to monitor Alvotech Warrant's management team and ensure that shareholders' interests are well served. Alvotech Warrant's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alvotech Warrant's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christina Siniscalchi, Interim Officer | ||
| Ming Li, Chief Officer | ||
| Sandra Casaca, Chief Officer | ||
| Anil Okay, Chief Officer | ||
| RoseMarie Ohlsson, Chief Officer | ||
| Giedrius Zunda, Chief Officer | ||
| Sean Gaskell, Chief Officer | ||
| Joel Morales, Chief Officer | ||
| Joseph McClellan, Chief Officer | ||
| Eva Gunnlaugsdottir, Vice Culture | ||
| Tanya Zharov, General Counsel | ||
| Faysal Kalmoua, COO Director | ||
| Mark Levick, Chief Officer | ||
| Sigridur Gudlaugsdottir, VP HR | ||
| Reem Malki, Chief Officer | ||
| Jenny Steingrimsdottir, Vice Culture | ||
| Robert Wessman, Ex Directors |
Alvotech Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alvotech Warrant a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.0761 | ||||
| Profit Margin | (2.00) % | ||||
| Operating Margin | 0.46 % | ||||
| Number Of Shares Shorted | 25.47 K | ||||
| Revenue | 91.43 M | ||||
| EBITDA | (484.86 M) | ||||
| Net Income | (551.73 M) | ||||
| Total Debt | 1.08 B | ||||
| Current Ratio | 1.07 X | ||||
| Book Value Per Share | (3.50) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Alvotech Stock Analysis
When running Alvotech Warrant's price analysis, check to measure Alvotech Warrant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alvotech Warrant is operating at the current time. Most of Alvotech Warrant's value examination focuses on studying past and present price action to predict the probability of Alvotech Warrant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alvotech Warrant's price. Additionally, you may evaluate how the addition of Alvotech Warrant to your portfolios can decrease your overall portfolio volatility.